NeuroMetrix, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NURO research report →
Price Chart
About the company
NeuroMetrix, Inc. is a healthcare company focused on creating, manufacturing, and distributing medical devices that stimulate and evaluate nerve function for both diagnostic and therapeutic applications. These products are available across a wide geographical area, including the United States, Europe, Japan, China, the Middle East, and Mexico.
- CEO
- Shai N. Gozani
- IPO
- 2004
- Employees
- 13
- HQ
- Woburn, MA, US
Get TickerSpark's AI analysis on NURO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $9.43M
- P/E
- -1.16
- PEG
- -0.03
- P/S
- 3.11
- P/B
- 0.63
- EV/EBITDA
- -0.95
- Div Yield
- 0.00%
- Gross Margin
- 55.38%
- Op Margin
- -289.57%
- Net Margin
- -257.38%
- ROE
- -45.38%
- ROIC
- -60.91%
Latest fiscal year · YoY change
- Revenue
- $3.03M-48.6%
- Gross Profit
- $1.68M-57.4%
- Op Income
- $-8,782,037
- Net Income
- $-7,806,055-19.6%
- EPS
- $-3.96+36.8%
- OCF Growth
- -17.1%
- FCF Growth
- -13.7%
- 52W High
- $4.73
- 52W Low
- $2.66
- 50D MA
- $4.39
- 200D MA
- $4.01
- Beta
- 1.83
- RSI (14)
- 66
- Avg Volume
- 11.50K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
NeuroMetrix posted a smaller Q4 quarter on lower DPNCheck revenue, while Quell Fibromyalgia showed early commercial traction and the company launched a strategic review amid Medicare Advantage disruption.· February 24, 2024
- Q4 revenue was $1.3 million, with DPNCheck still about 80% of sales but down 32% year over year.
- Full-year 2023 revenue fell 29% to $5.9 million, mainly due to CMS Medicare Advantage rule changes impacting DPNCheck.
- Quell Fibromyalgia showed early momentum: unique prescribers rose to 199 from 125 in Q3, prescriptions increased to 583 from 262, and refills rose to 525 from 315.
- Gross margin was 64.4% in Q4 and about 67% for the full year; management said DPNCheck should still generate positive cash flow despite lower revenue.
- The company ended 2023 with about $18 million in liquid assets and is reviewing strategic options, including possible asset sales, mergers, or other transactions.
Q4 2023 revenue was $1.3 million, down 32% from Q4 2022 for DPNCheck, which remained about 80% of revenue. Full-year 2023 revenue was $5.9 million, down 29% from $8.3 million in 2022. Gross profit was about $850,000 in Q4, with gross margin of 64.4%, versus $1.2 million of gross profit in Q4 2022; full-year gross profit was $3.9 million at about a 67% margin, down from $5.8 million and just under 70% in 2022. Q4 net loss was $1.6 million, or $1.43 per share, versus just under $700,000, or $0.73 per share, a year ago; full-year net loss was $6.5 million, or $6.27 per share, versus $4.4 million, or $4.97 per share in 2022. The company ended the quarter with about $18 million in liquid assets, used about $1.4 million of operating cash in Q4, and said annual cash usage averaged about $1.5 million per quarter in 2023. No formal numeric revenue guidance was provided; management said DPNCheck revenue is not expected to reverse this year, while Quell Fibromyalgia is hoped to become material revenue this year.
Shai Gozani framed the strategy around three priorities: grow Quell Fibromyalgia in the U.S., advance Quell Neurotherapeutics into additional indications, and adapt DPNCheck to a changed reimbursement environment. He sounded constructive on Quell, noting early prescription and refill growth, telehealth and pharmacy support, and continued work on CIPN and long COVID. At the same time, he acknowledged that the Medicare Advantage rule changes have materially hurt DPNCheck and said the company is exploring broader value-based care, retail healthcare, and strategic alternatives.
Thomas Higgins focused on the financial bridge: Q4 revenue was $1.3 million, gross profit about $850,000, gross margin 64.4%, operating expenses $2.7 million, and net loss $1.6 million, or $1.43 per share. He said full-year revenue was $5.9 million, gross profit $3.9 million at about a 67% margin, OpEx $11.1 million, and net loss $6.5 million, or $6.27 per share. He also emphasized liquidity of about $18 million, quarterly operating cash usage of about $1.4 million, and around $1.9 million of ATM sales in Q4, with about $1.6 million settled in the quarter.
Analysts pressed on whether DPNCheck could expand beyond the Medicare Advantage channel into the broader diabetes market, and management said that broader diabetes and other value-based care opportunities are part of the strategic review. Another question challenged the use of the ATM, with the analyst arguing for a traditional institutional offering instead; management responded that the company is a cash consumer, that micro-cap pipe deals have been difficult, and that the ATM lets it sell shares in smaller amounts when opportunities arise. Management also confirmed there is a CPT code, but said screening reimbursement remains the core challenge because most insurers do not reimburse screening tests the way they reimburse clinical tests.
The positive case is that Quell Fibromyalgia is showing real early traction, with more prescribers, more prescriptions, and more refills quarter over quarter. Management also pointed to a pipeline beyond fibromyalgia, including a CIPN 510(k) filing and long COVID data, which could expand the addressable market if regulatory progress continues.
The main risk is that DPNCheck’s historical core market has been disrupted by CMS policy changes, and management explicitly said they do not expect a reversal in revenue this year. Quell is still early and cash pay outside certain VA facilities, while the company continues to burn cash and may rely on ATM sales or strategic transactions to support the business.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 73.7%
- Shares Outstanding
- 2.06M
- Float Shares
- 1.52M
of shares held by institutions
16 13F filers
Buy/sell ratio 0.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock Inc. | 5.01K | 0 |
| Sutton Wealth Advisors Inc. | 320 | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 1, 25 | Horowitz Joshua | sell | 60,500 |
| May 1, 25 | Goodman David | sell | 13,730 |
| May 1, 25 | Goodman David | sell | 7,602 |
| May 1, 25 | Van Avermaete David | sell | 7,601 |
| May 1, 25 | Van Avermaete David | sell | 13,730 |
| May 1, 25 | HIGGINS THOMAS T | sell | 3,308 |
| May 1, 25 | HIGGINS THOMAS T | sell | 11,840 |
| May 1, 25 | KATZ NANCY E | sell | 7,602 |
| May 1, 25 | KATZ NANCY E | sell | 13,730 |
| May 1, 25 | Gozani Shai | sell | 15,466 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NURO coverage
Recent articles, reports, and earnings notes.
No research on NURO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NURO report →electroCore Completes Acquisition of NeuroMetrix, Gaining Access to its Quell Platform, Creating Significant Player in Non-Invasive Bioelectronic Technologies
globenewswire.com · May 2
NEUROMETRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NeuroMetrix, Inc. - NURO
businesswire.com · Jan 6
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of NeuroMetrix, Inc. - NURO
prnewswire.com · Dec 18
NURO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of NeuroMetrix, Inc. Is Fair to Shareholders
businesswire.com · Dec 17
electroCore to Acquire NeuroMetrix, Gaining Access to its Quell Platform and Positioning Itself as a Significant Player in Non-Invasive Bioelectronic Medicine and Wellness
globenewswire.com · Dec 17
NeuroMetrix to be Acquired by electroCore
globenewswire.com · Dec 17
NeuroMetrix Q3 Loss Narrows Y/Y, Quell Sales Drives Growth
zacks.com · Nov 6
NeuroMetrix Reiterates its Review of Strategic Alternatives
globenewswire.com · Aug 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.